KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Invested Capital (2016 - 2025)

Historic Invested Capital for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $46.5 billion.

  • Gilead Sciences' Invested Capital rose 1162.85% to $46.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 billion, marking a year-over-year increase of 1162.85%. This contributed to the annual value of $46.0 billion for FY2024, which is 355.29% down from last year.
  • Latest data reveals that Gilead Sciences reported Invested Capital of $46.5 billion as of Q3 2025, which was up 1162.85% from $44.6 billion recorded in Q2 2025.
  • Gilead Sciences' Invested Capital's 5-year high stood at $49.9 billion during Q2 2021, with a 5-year trough of $41.5 billion in Q2 2024.
  • Over the past 5 years, Gilead Sciences' median Invested Capital value was $46.3 billion (recorded in 2023), while the average stood at $46.1 billion.
  • In the last 5 years, Gilead Sciences' Invested Capital soared by 15914.39% in 2021 and then tumbled by 1182.66% in 2024.
  • Gilead Sciences' Invested Capital (Quarter) stood at $47.8 billion in 2021, then decreased by 2.77% to $46.4 billion in 2022, then grew by 2.8% to $47.7 billion in 2023, then fell by 3.55% to $46.0 billion in 2024, then rose by 0.96% to $46.5 billion in 2025.
  • Its Invested Capital stands at $46.5 billion for Q3 2025, versus $44.6 billion for Q2 2025 and $44.1 billion for Q1 2025.